Ultragenyx Pharmaceutical Inc.
RARE
$26.96
$0.160.60%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Net Income | 50.27% | -43.91% | 28.74% | -56.88% | 23.84% |
| Total Depreciation and Amortization | 0.00% | -8.94% | 2.08% | -4.38% | 0.00% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -48.39% | 60.17% | -24.18% | 27.63% | -37.50% |
| Change in Net Operating Assets | 43.14% | -8,773.47% | -98.93% | 338.52% | 58.93% |
| Cash from Operations | 50.76% | -97.34% | -9.19% | 16.13% | 34.34% |
| Capital Expenditure | 0.00% | -6.61% | 26.60% | 57.40% | -200.00% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 193.75% | 32.69% | -160.20% | 60.08% | -38.84% |
| Cash from Investing | 189.80% | 32.18% | -161.65% | 65.05% | -40.83% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -- | -- | 109,500.00% | -100.00% | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -- | -- | 19,709,500.00% | -100.00% | 53,403.18% |
| Foreign Exchange rate Adjustments | 200.00% | -52.44% | -323.13% | -92.65% | 300.00% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 80.16% | -211.53% | 749.97% | -47.89% | 211.11% |